Published in Tumori on July 27, 2006
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol (2005) 3.93
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol (2005) 3.48
Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer. Cancer Res (2007) 3.22
STAT proteins: from normal control of cellular events to tumorigenesis. J Cell Physiol (2003) 3.04
miR-20b modulates VEGF expression by targeting HIF-1 alpha and STAT3 in MCF-7 breast cancer cells. J Cell Physiol (2010) 1.74
Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood (2003) 1.65
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer (2010) 1.56
Improvement of wound healing after hemorrhoidectomy: a double-blind, randomized study of botulinum toxin injection. Dis Colon Rectum (2005) 1.48
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev (2010) 1.45
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? Cancer Treat Rev (2010) 1.15
Pterostilbene and 3'-hydroxypterostilbene are effective apoptosis-inducing agents in MDR and BCR-ABL-expressing leukemia cells. Int J Biochem Cell Biol (2005) 1.13
Management of painful bone metastases. Curr Opin Oncol (2007) 1.12
Heterocyclic and phenyl double-bond-locked combretastatin analogues possessing potent apoptosis-inducing activity in HL60 and in MDR cell lines. J Med Chem (2005) 1.10
Activin A circulating levels in patients with bone metastasis from breast or prostate cancer. Clin Exp Metastasis (2006) 1.06
Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management. Eur J Pain (2008) 1.04
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Cathepsin D expression levels in nongynecological solid tumors: clinical and therapeutic implications. Clin Exp Metastasis (2004) 1.00
Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Sci Rep (2015) 0.99
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases. Cancer (2007) 0.98
Galangin increases the cytotoxic activity of imatinib mesylate in imatinib-sensitive and imatinib-resistant Bcr-Abl expressing leukemia cells. Cancer Lett (2008) 0.97
MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone. Anticancer Res (2007) 0.96
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome. Clin Cancer Res (2008) 0.93
Serum interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med Oncol (2008) 0.92
Design, synthesis, and biological evaluation of novel aminobisphosphonates possessing an in vivo antitumor activity through a gammadelta-T lymphocytes-mediated activation mechanism. J Med Chem (2008) 0.90
Botulinum toxin vs. topical glyceryl trinitrate ointment for pain control in patients undergoing hemorrhoidectomy: a randomized trial. Dis Colon Rectum (2006) 0.90
The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncology (2010) 0.89
Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics (2007) 0.89
Prognostic significance of p16INK4a alterations and 9p21 loss of heterozygosity in locally advanced laryngeal squamous cell carcinoma. J Cell Physiol (2002) 0.88
Irinotecan (CPT-11) and mitomycin-C (MMC) as second-line therapy in advanced gastric cancer: a phase II study of the Gruppo Oncologico dell' Italia Meridionale (prot. 2106). Am J Clin Oncol (2005) 0.88
Serum follistatin in patients with prostate cancer metastatic to the bone. Clin Exp Metastasis (2010) 0.87
Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer (2002) 0.87
First-line treatment with epirubicin and vinorelbine in metastatic breast cancer. J Clin Oncol (2002) 0.86
Have p53 gene mutations and protein expression a different biological significance in colorectal cancer? J Cell Physiol (2002) 0.86
Cytokines and growth factors in wound drainage fluid from patients undergoing incisional hernia repair. Wound Repair Regen (2006) 0.86
Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine. J Pain Symptom Manage (2007) 0.86
Gemcitabine-based doublets versus single-agent therapy for elderly patients with advanced nonsmall cell lung cancer: a Literature-based Meta-analysis. Cancer (2009) 0.85
Stilbene-based anticancer agents: resveratrol analogues active toward HL60 leukemic cells with a non-specific phase mechanism. Bioorg Med Chem Lett (2006) 0.85
Tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Anticancer Agents Med Chem (2009) 0.84
Morphine versus oxycodone in pancreatic cancer pain: a randomized controlled study. Clin J Pain (2010) 0.84
p53 mutations in L3-loop zinc-binding domain, DNA-ploidy, and S phase fraction are independent prognostic indicators in colorectal cancer: a prospective study with a five-year follow-up. Cancer Epidemiol Biomarkers Prev (2002) 0.84
Antiproliferative agents that interfere with the cell cycle at the G1-->S transition: further development and characterization of a small library of stilbene-derived compounds. ChemMedChem (2008) 0.84
EGFR genomic alterations in cancer: prognostic and predictive values. Front Biosci (Elite Ed) (2011) 0.84
Serum VEGF and b-FGF profiles after tension-free or conventional hernioplasty. Langenbecks Arch Surg (2005) 0.84
TP53 in gastric cancer: mutations in the l3 loop and LSH motif DNA-binding domains of TP53 predict poor outcome. J Cell Physiol (2004) 0.84
Modifications in the production of cytokines and growth factors in drainage fluids following mesh implantation after incisional hernia repair. Am J Surg (2006) 0.84
Treatment strategies for cancer patients with breakthrough pain. Expert Opin Pharmacother (2009) 0.83
Acute inflammatory response after inguinal and incisional hernia repair with implantation of polypropylene mesh of different size. Langenbecks Arch Surg (2005) 0.82
Bone metastases in soft tissue sarcoma: a survey of natural history, prognostic value and treatment options. Clin Sarcoma Res (2013) 0.82
Identification of a terphenyl derivative that blocks the cell cycle in the G0-G1 phase and induces differentiation in leukemia cells. J Med Chem (2006) 0.82
Nm23-H1 expression does not predict clinical survival in colorectal cancer patients. Oncol Rep (2003) 0.82
Bortezomib: a new pro-apoptotic agent in cancer treatment. Curr Cancer Drug Targets (2010) 0.82
Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage (2006) 0.82
Minor hepatic resection using heat coagulative necrosis. Am Surg (2009) 0.81
BRCA1 genetic testing in 106 breast and ovarian cancer families from Southern Italy (Sicily): a mutation analyses. Breast Cancer Res Treat (2007) 0.81
Meaningful cut-off pain intensity for breakthrough pain changes in advanced cancer patients. Curr Med Res Opin (2012) 0.81
[Efficacy of topical use of 0.2% glyceryl trinitrate in reducing post-haemorrhoidectomy pain and improving wound healing]. Chir Ital (2005) 0.80
Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study. Semin Oncol (2004) 0.80
Lenograstim in preventing chemotherapy-induced febrile neutropenia in patients with soft tissue sarcoma. Anticancer Res (2013) 0.80
Factors involved in gastrointestinal bleeding in advanced cancer patients followed at home. Support Care Cancer (2003) 0.80
Gemcitabine (GEM) plus oxaliplatin, folinic acid, and 5-fluorouracil (FOLFOX-4) in patients with advanced gastric cancer. Cancer Chemother Pharmacol (2005) 0.80
Prevention of venous thromboembolism in patients with cancer: guidelines of the Italian Society for Haemostasis and Thrombosis (SISET)(1). Thromb Res (2011) 0.80
Overexpression of cyclin D1 and interaction between p27Kip1 and tumour thickness predict lymph node metastases occurrence in lower lip squamous cell carcinoma. Oral Oncol (2005) 0.79
TP53 mutations and S-phase fraction but not DNA-ploidy are independent prognostic indicators in laryngeal squamous cell carcinoma. J Cell Physiol (2006) 0.79
Pain mechanisms involved and outcome in advanced cancer patients with possible indications for celiac plexus block and superior hypogastric plexus block. Tumori (2002) 0.79
PML down-regulation in soft tissue sarcomas. J Cell Physiol (2010) 0.79
A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care (2007) 0.79
Clinical presentation and treatment of gastrointestinal stromal tumors. Tumori (2006) 0.79
Anti-endothelin drugs in solid tumors. Expert Opin Emerg Drugs (2010) 0.78
Long-term manometric study of anal sphincter function after hemorrhoidectomy. Int J Colorectal Dis (2006) 0.78
Effects of zoledronic acid on proteinase plasma levels in patients with bone metastases. Anticancer Res (2006) 0.77
Studies on the apoptotic activity of natural and synthetic retinoids: discovery of a new class of synthetic terphenyls that potently support cell growth and inhibit apoptosis in neuronal and HL-60 cells. J Med Chem (2005) 0.77
A new germline mutation in BRCA1 gene in a sicilian family with ovarian cancer. Breast Cancer Res Treat (2005) 0.77
Interleukin-2, interferon-alpha and medroxyprogesterone acetate in metastatic renal cell carcinoma. Anticancer Res (2003) 0.77
Managing cancer patients with acute venous thromboembolism: exploring safe alternatives to hospitalisation. Exp Oncol (2004) 0.77
PML expression in soft tissue sarcoma: prognostic and predictive value in alkylating agents/antracycline-based first line therapy. J Cell Physiol (2012) 0.77
Sequential docetaxel followed by epirubicin-vinorelbine as first-line chemotherapy in advanced breast cancer. Anticancer Res (2005) 0.76
Surgical treatment of extravasation injuries. J Surg Oncol (2005) 0.75
Corrigendum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases. Sci Rep (2016) 0.75
Biweekly combination of trastuzumab, docetaxel and gemcitabine for HER2-positive metastatic breast cancer: results of a Phase II GOIM study. Future Oncol (2014) 0.75
[Oral complications in patients with head and neck cancer after radio-chemotherapy. Mucositis and xerostomia]. Recenti Prog Med (2007) 0.75